SCHEMBL8950842

SCHEMBL8950842

C[C@@H]([C@H](O)CCl)N(Cc1ccccc1)Cc1ccccc1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 5/20 0.44
ALDH1A1 P00352 4/20 0.44
SMN1; SMN2 Q16637 3/20 0.44
ADRA2B P18089 2/20 0.44
ADRA2C P18825 2/20 0.44
SLC6A2 P23975 2/20 0.44
HTR2A P28223 2/20 0.44
ADRA1A P35348 2/20 0.44
SLC6A3 Q01959 2/20 0.44
KCNH2 Q12809 2/20 0.44
SLC22A2 O15244 1/20 0.44
SLC22A1 O15245 1/20 0.44
SLC22A3 O75751 1/20 0.44
ESR1 P03372 1/20 0.44
CHRM2 P08172 1/20 0.44
HTR1A P08908 1/20 0.44
ADRA2A P08913 1/20 0.44
ADORA3 P0DMS8 1/20 0.44
CHRM1 P11229 1/20 0.44
DRD2 P14416 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8950839 1.00 TSHR (0.44) TSHRALDH1A1SMN1; SMN2ADRA2BADRA2C
SCHEMBL14541169 1.00 TSHR (0.44) TSHRALDH1A1SMN1; SMN2ADRA2BADRA2C
SCHEMBL5654192 0.84 TRPA1 (0.55) TSHRALDH1A1ADRA2BADRA2CSLC6A2
SCHEMBL8382957 0.83 TRPA1 (0.45) TSHRALDH1A1SMN1; SMN2ADRA2BADRA2C
SCHEMBL8382959 0.83 TRPA1 (0.45) TSHRALDH1A1SMN1; SMN2ADRA2BADRA2C
SCHEMBL26987985 0.81 TSHR (0.46) TSHRALDH1A1SMN1; SMN2ADRA2BADRA2C
SCHEMBL26989268 0.81 TSHR (0.46) TSHRALDH1A1SMN1; SMN2ADRA2BADRA2C
SCHEMBL26988540 0.81 TSHR (0.46) TSHRALDH1A1SMN1; SMN2ADRA2BADRA2C
SCHEMBL428101 0.81 TSHR (0.46) TSHRALDH1A1SMN1; SMN2ADRA2BADRA2C
SCHEMBL26988083 0.81 TSHR (0.46) TSHRALDH1A1SMN1; SMN2ADRA2BADRA2C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-5550291-A Process for key intermediates for HIV protease inhibitors BIO-MEGA/BOEHRINGER INGELHEIM RESEARCH, INC. (CA) 1996-08-27 US disclosed